The Board (the Board')of Directors (the Directors') of Sinco Pharmaceuticals Holdings Limited (the Company', together with its subsidiaries, the Group') that with effect from 29 March 2023, Mr. Huang Xiangbin (Mr. Huang') has tendered to the Board his resignation as a co-chief executive officer of the Company due to the need to devote more time to his other business commitment. Mr. Jin Min ("Mr. Jin"), will become the chief executive officer of the Company. Mr. Jin's term of office, remuneration, other titles and positions remain unchanged.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.232 HKD | 0.00% | -4.53% | -3.33% |
05-16 | Sinco Pharmaceuticals Holdings Limited Approves Dividend for the Year Ended 31 December 2023 | CI |
03-27 | Sinco Pharmaceuticals' 2023 Profit Declines on Higher Tax Payments | MT |
1st Jan change | Capi. | |
---|---|---|
-3.33% | 60.42M | |
+26.13% | 75.01B | |
-5.35% | 22.83B | |
+15.24% | 8.76B | |
-6.01% | 7.84B | |
-33.02% | 6.68B | |
+20.94% | 5.59B | |
+4.33% | 4.21B | |
-3.66% | 4.05B | |
+12.62% | 3.41B |
- Stock Market
- Equities
- 6833 Stock
- News Sinco Pharmaceuticals Holdings Limited
- Sinco Pharmaceuticals Holdings Limited Announces Chief Executive Officer Changes